Back to results
US 8,617,556 B2Granted
Gram-positive bacteria specific binding compounds
AssigneesGenentech, Inc., Aimm Therapeutics B.V.
InventorsTim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
Life of this patent
Estimating the term…
Abstract
The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Claims74
An isolated antibody comprising:
- (a) a heavy chain CDR1 sequence RFAMS (SEQ ID NO:1), and
- (b) a heavy chain CDR2 sequence SINNGNNPYYARSVQY (SEQ ID NO:2) or SINSGNNPYYARSVQY (SEQ ID NO:60), and
- (c) a heavy chain CDR3 sequence DHPSSGWPTFDS (SEQ ID NO:3), and
- (d) a light chain CDR1 sequence RASENVGDWLA (SEQ ID NO:4), and
- (e) a light chain CDR2 sequence KTSILES (SEQ ID NO:5), and
- (f) a light chain CDR3 sequence QHYXRFPYT (SEQ ID NO:6), wherein X is I or M.
3 more elements
A method of treating a gram-positive bacterium-related disorder comprising administering to an individual in need thereof a therapeutically effective amount of an antibody comprising:
- (a) a heavy chain CDR1 sequence RFAMS (SEQ ID NO:1), and
- (b) a heavy chain CDR2 sequence SINNGNNPYYARSVQY (SEQ ID NO:2) or SINSGNNPYYARSVQY (SEQ ID NO:60), and
- (c) a heavy chain CDR3 sequence DHPSSGWPTFDS (SEQ ID NO:3), and
- (d) a light chain CDR1 sequence RASENVGDWLA (SEQ ID NO:4), and
- (e) a light chain CDR2 sequence KTSILES (SEQ ID NO:5), and
- (f) a light chain CDR3 sequence QHYXRFPYT (SEQ ID NO:6), wherein X is I or M.
3 more elements
Dependencies are inferred from the claim text.